SELLAS Life Sciences Group (SLS) Proxy filing summary

Executive summary

• Annual meeting scheduled for June 16, 2026, to be held virtually for shareholder participation.

• Shareholders are encouraged to review proxy materials and vote by June 15, 2026.

Voting matters and shareholder proposals

• Election of two Class I directors for a three-year term expiring at the 2029 annual meeting.

• Ratification of Baker Tilly US, LLP as independent auditor for fiscal year ending December 31, 2026.

• Approval to amend the 2023 Equity Incentive Plan to increase authorized shares by 20,000,000.

• Advisory approval of executive compensation (say-on-pay) for named executive officers.

• Approval for potential postponement or adjournment of the annual meeting to solicit additional proxies or establish a quorum.

Board of directors and corporate governance

• Nominees for Class I director positions are Robert Van Nostrand and Jane Wasman.